Senti Biosciences, Inc. (SNTI)
| Market Cap | 103.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.31M |
| Shares Out | 26.00M |
| EPS (ttm) | -12.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,920 |
| Open | 3.910 |
| Previous Close | 3.880 |
| Day's Range | 3.900 - 3.910 |
| 52-Week Range | 1.520 - 16.940 |
| Beta | 2.33 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+207.69%) |
| Earnings Date | May 8, 2025 |
About SNTI
Senti Biosciences, Inc. operates as a clinical-stage biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (“NK”) cells to create CAR-NK cells outfitted with gene circuit technologies in several oncology indications with high unmet need. The company product candidates include SENTI-202, is a potentially first-in-class Logic Gated off-the-sh... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for SNTI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.
News
Senti Bio Participates in a Virtual Investor KOL Connect Segment
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, Pr...
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ET Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23r...
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early cl...
Senti Bio Joins Webull Corporate Connect Service Platform
Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment of acute myeloid leukemia (AML)
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation...
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Stren...
Senti Bio Appoints Feng Hsiung to Board of Directors
– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) – – Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –
Senti Bio Strengthens Leadership Team with Strategic Hires
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif....
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) –
Senti Biosciences Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Why Is Senti Biosciences Stock Surging Over 400% On Monday?
Senti Biosciences, Inc. SNTI stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile –
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 Enrollment contin...
Senti Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene ...
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using it...
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024 Shares expected to begin trading on split-adjusted basis on July 18, 2024
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using it...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FR...
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLO...
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data supports the design of Phase 1 clinical trial of SENTI-202 with patien...
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 –
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 ...
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potenti...